strong close continu
view thesi balanc
close strong note revenu came
expect nice contribut core organ growth ex-blood
screen vs forecast rel model half beat came
consid core area breast health sale post estim
organ growth beat forecast continu defi convent
think around durat tomo-tail despit penetr
current mammographi instal base growth continu augment servic
intern contribut new product gyn surgic sale
post organ growth beat forecast growth continu
led myosur new product novasur appear stabil medic
aesthet sale beat expect post organ
growth said segment easi comp took anoth
charg quarter cumul write-down repres
origin cynosur deal valu half beat came non-cor area
specif blood screen vs forecast mdx remain strong
organ growth although line expect done good job
sustain panther placement consum growth new aptima menu
expans cytolog perinat line forecast ex-fx
initi guidanc look right middl compar
expect compani revenu guidanc call organ growth vs
prior forecast adj ep expect rang repres
growth y/i vs street overal believ valuat
ebitda fair given growth rate done
admir job sustain growth new product recent tuck-in
help drive increment growth leverag compani infrastructur said
remain cautiou around durat placement breast given
posit cycl well potenti greater mdx competit
reiter equal weight rate
quarterli annual ep usd
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
equal weight view thesi
balanc breast health segment post
durabl growth gyn surgic appear
competit well posit said believ
mdx segment could face new price pressur
due competit activ limit
convict cynosur abil acceler
upsid case repres upsid
ebitda potenti lever
upsid includ better growth intern market
capit deploy improv growth new
downsid case repres
downsid ebitda potenti risk
includ greater expect competit activ
mdx well continu pressur medic
aesthet cynosur
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
close strong note revenu came
expect nice contribut core organ growth ex-blood
screen vs forecast rel model half beat came
would consid core area breast health sale post estim
organ growth beat forecast compani continu defi
convent think around durat tomo-tail despit
penetr current mammographi instal base growth continu augment
servic intern contribut new product gyn surgic
sale post organ growth beat forecast growth continu
led myosur new product novasur appear stabil medic
aesthet sale actual beat expect post organ
growth said segment easi comp compani took anoth
charg quarter cumul write-down repres
origin cynosur deal valu half beat came non-cor area
specif blood screen vs forecast mdx remain strong organ
growth although line expect compani done good job
sustain panther placement consum growth new aptima menu
expans cytolog perinat also line forecast ex-
also initi guidanc look right middl compar
expect compani revenu guidanc call organ growth vs
prior forecast adj ep expect rang repres
growth y/i vs forecast street overal believ
valuat ebitda fair given growth rate done
admir job sustain growth new product recent tuck-in help
drive increment growth leverag compani infrastructur said remain
cautiou around durat placement breast given posit
cycl well potenti greater mdx competit roch abbott bring new
product market reiter equal weight rate
initi revenu ep guidanc line prior estim
revenu anticip rang billion repres report growth
y/i embed target headwind fx adjust
 contribut headwind lower blood screen revenu expect off-set
estim organ growth expect rang
guid toward ep repres growth ep
expect ramp sequenti year progress gross margin expect
improv lower manufactur cost improv product mix absorpt benefit new
product sale cost reduct effort partial off-set expans lower
margin intern busi expens expect increas
guid tax rate dilut share count million mid-
guidanc call revenu million repres growth
y/i constant currenc growth anticip rang
normal year expect ep expect rang
repres growth y/i compani expect superson imagin
acquisit close end revenu contribut quarter
said model dilut deal given minor stake
compani
revenu increas y/i million organ revenu grew y/i
growth solid us intern ex-u addit
segment regist growth quarter
revenu organ growth
look segment post growth segment
diagnost revenu segment revenu grew y/i ex-fx
molecular diagnost increas y/i ex-fx driven increas placement
util panther system notabl intern molecular diagnost grew
ex-fx organ driven continu traction panther placement
compani full menu sexual health viral load respiratori assay
market global optimist compani recent approv aptima
mycoplasma genitalium assay add compani exist sexual health
revenu segment
menu total panther place diagnost custom
locat intern averag util per instrument exce
cytolog perinat revenu increas ex-fx million
declin revenu perinat off-set modest growth cytolog overal
diagnost revenu exceed expect driven greater
contribut non-cor blood screen revenu vs
breast revenu revenu grew y/i ex-fx acquisit ad
growth impli segment post organ growth
observ four detail overview holog breast health
perform quarter
cynosur rev revenu grew y/i ex-fx revenu
come expect specif due fda letter
compani women health busi see soft compani note
busi environ chang much businesss skin franchis continu
perform well see stabil salesforc
gyn surgic revenu increas y/i ex-fx million within
growth rate myosur healthi grower novasur revenu declin
myosur benefit new product includ omni hysteroscop
skelet health revenu increas y/i ex-fx
breast health deliv organ growth driven combin resili
 placement servic growth new product us breast health busi
improv y/i ex-fx intern busi grew ex-fx includ
specif breast imag compani report million revenu
y/i ex-fx holog breast imag busi benefit strong servic
growth larger busi gantri new product
perform new platform help upgrad exist
user compani also monet instal base platform
upgrad intellig clariti hd smartcurv product remind
compani past penetr instal base total
market instal base intern compani post ex-fx
growth breast imag revenu quarter
intervent breast solut revenu million grew ex-fx new
product includ brevera strong contributor recent quarter said
compani modestli expect note
constrain capit side wherea biopsi consum post strong growth
remind saw acceler ffdm placement rate earli
acceler driven factor
includ reimburs
mammographi addit renew invest sale market ge
siemen back launch new unit keep mind calendar fourth
quarter year typic season weak given time rsna
confer loss sell week
quarterli placement ffdm unit
octob fda report monthli increas mammographi unit
field mark improv octob remain elev
unit placement unit placementstot unitsdigit unitsquarterli unit place barclay holog inc
monthli placement ffdm unit
rate seen septemb one month placement
quarterli target industri caveat monthli data volatil
given fda survey methodolog believ data much reliabl
longer period time unit increas unit octob continu
fluctuat monthli replac occur
gross margin declin y/i driven number factor
margin advers impact higher manufactur cost fx tariff mix
barclay holog inc
gross margin annual improv
non-gaap ep increas y/i line model
dilut share count million line model
non-gaap ep growth
oper margin improv y/i driven higher
revenu lower sg percentag revenu sale market ex-comp came
revenu y/i expens revenu ex-comp
y/i ex-comp revenu y/i
adjust ex-comp sg trend
final capit deploy continu repres opportun thesi
compani guidanc assum share count increment
capit deploy buy-back would repres potenti upsid forecast
compani exit quarter net debt/ebitda ratio follow portfolio
chang compani leverag remain point pursu addit
capit deploy believ compani priorit tuck-in acquisit absent
 would expect compani pay debt repurchas share
repurchas share go forward believ breast health gyn
surgic diagnost like area could augment
breast health leverag compani commerci breadth drive new
product growth suit detail observ four recent
complet two tuck-in area includ faxitron bioptic
think good exampl tuck-in acquisit make sens fit
compani strategi
gyn surgic could also attract area tuck-in addit product
 ad product gyn surgic portfolio would better leverag gyn
sale forc third product market ob/gyn
diagnost point care poc notabl gap compani portfolio
critiqu poc market mani compani
success gener profit said point care one
fastest grow area coverag sustain secular tailwind relat
consumer healthcar would natur cross-sel opportun
hospit touch point panther mdx system
product revssg rev barclay holog inc
net debt ttm ebitda
debt ebitda barclay holog inc
estestestestestestestincom statement y/i q/q y/i q/q y/i growth y/i growth y/i ex-fx organ ex-sel q/q product sale product product revenu inc servic gross gross margin inc y/i sale y/i stock comp sg y/i ebitda y/i oper incom ebit y/i invest expens outstand incom pre-tax y/i benefit incom tax net incom adj net y/i dilut y/i net barclay holog inc
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
